

Erratum

Erratum to “Design, synthesis and structure–activity relationships of 6-*O*-arylpropargyl diazalides with potent activity against multidrug-resistant *Streptococcus pneumoniae*”
[Bioorg. Med. Chem. Lett. 15 (2005) 2653]

Hong Yong,^{*,†} Yu Gui Gu, Richard F. Clark, Thomas Marron, Zhenkun Ma, Niru Soni, Gregory G. Stone, Angela M. Nilius, Kennan Marsh and Steven W. Djuric

Infectious Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60044, USA

Available online 31 May 2005

The publisher would like to apologize for mistakes made in the layout of [Table 1](#). The table appears on the next page.

DOI of original article: 10.1016/j.bmcl.2005.03.011.

^{*} Corresponding author. Tel.: +1 847 938 6939; fax: +1 847 938 1674; e-mail: hong.yong@abbott.com

[†] At present address: Abbott Laboratories, D47H, AP10-3, 100 Abbott Park Road, IL 60064-6112, USA.

Table 1. Antibacterial activity of 6-*O*-arylpropargyl diazalides and homologues (MIC, µg/mL)

Comps	Ar	MIC (µg/mL) ^a							
		<i>S. aureus</i> 6538P	<i>S. aureus</i> A5177	<i>S. pyogene</i> EES61	<i>S. pyogene</i> 930	<i>S. pneumoniae</i> ATCC6303	<i>S. pneumoniae</i> 5979	<i>S. pneumoniae</i> 5649	<i>H. influenzae</i> GYR1435
Ery^b		0.39	6.2	0.03	>128	0.06	>128	16	8
ABT-773		0.05	0.05	<0.005	1	0.03	16	0.25	2
TE-802		0.1	0.1	0.06	>128	0.06	>128	1	4
6a		0.2	0.2	0.06	64	0.03	>128	0.5	8
6b		0.2	0.2	0.03	64	0.03	>128	1	2
6c		0.1	0.1	0.03	64	0.03	>128	0.25	4
6d		0.1	0.1	0.015	1	≤0.004	2	0.25	2
6e		0.06	0.1	≤0.008	0.5	0.004	4	0.25	2
6f		0.25	0.06	≤0.008	4	≤0.008	8	0.06	2
6g		0.5	0.125	≤0.008	2	≤0.008	0.003	0.06	4
6h		0.5	0.03	≤0.008	4	≤0.008	≤0.008	≤0.008	2
6i		0.25	0.03	≤0.008	8	≤0.008	≤0.008	≤0.008	1
7e		0.25	0.125	≤0.008	0.25	≤0.008	0.125	0.125	4
7g		0.5	0.125	≤0.008	2	≤0.008	0.125	0.25	4
10h		1	0.5	≤0.008	0.5	0.015	0.125	0.25	8
10i		0.25	0.25	≤0.008	0.5	≤0.008	0.03	0.06	2

^a Minimum inhibitory concentrations.^b Erythromycin A.